Search

Your search keyword '"Fritz, Daan"' showing total 18 results
Start Over Author "Fritz, Daan" Publication Year Range Last 10 years
18 results on '"Fritz, Daan"'

6. Neurosarcoidosis

Author

Fritz, Daan, van de Beek, Diederik, Brouwer, Matthijs C., Eftimov, Filip, Amsterdam Neuroscience - Neuroinfection & -inflammation, AII - Infectious diseases, and Graduate School

Published
2022

10. Clinical manifestations of neurosarcoidosis in the Netherlands

Author

Longziekten, Voortman, Mareye, Fritz, Daan, Vogels, OJM, van de Beek, D, De Vries, J, Brouwer, MC, Drent, M., Longziekten, Voortman, Mareye, Fritz, Daan, Vogels, OJM, van de Beek, D, De Vries, J, Brouwer, MC, and Drent, M.

Published
2019

13. Small fiber neuropathy: a disabling and underrecognized syndrome

Author

Longziekten, Voortman, Mareye, Fritz, Daan, Vogels, Oscar J M, Eftimov, Filip, van de Beek, Diederik, Brouwer, Matthijs C., Drent, Marjolein, Longziekten, Voortman, Mareye, Fritz, Daan, Vogels, Oscar J M, Eftimov, Filip, van de Beek, Diederik, Brouwer, Matthijs C., and Drent, Marjolein

Published
2017

14. Neurosarcoidosis in a Tertiary Referral Center

Author

Leonhard, Sonja E., Fritz, Daan, Eftimov, Filip, van der Kooi, Anneke J., van de Beek, Diederik, and Brouwer, Matthijs C.

Subjects
Adult, Male, Sarcoidosis, Observational Study, Middle Aged, Cohort Studies, Tertiary Care Centers, Cross-Sectional Studies, Central Nervous System Diseases, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, Humans, Female, Research Article
Abstract

Supplemental Digital Content is available in the text, The aim of this study was to evaluate clinical characteristics, diagnostic strategy, and treatment in patients with neurosarcoidosis in a tertiary referral centre. In a cross-sectional study, we included all patients with neurosarcoidosis treated at our tertiary referral center between September 2014 and April 2015. We identified 52 patients, among them 1 patient was categorized as having definite neurosarcoidosis, 37 probable neurosarcoidosis, and 14 possible neurosarcoidosis. Neurologic symptoms were the first manifestation of sarcoidosis in 37 patients (71%). Chronic aseptic meningitis was the most common presentation (19/52 patients [37%]), followed by cranial neuropathy (16/52 patients [31%]). Serum angiotensin-converting enzyme and lysozyme levels were elevated in 18 of 41 (44%) and 12 of 26 cases (46%). Pulmonary or lymph node sarcoidosis was identified by chest X-ray in 21 of 39 cases (54%) and by computed tomography of the chest in 25 of 31 cases (81%); 18Fluorodeoxyglucose-Positron emission tomography showed signs of sarcoidosis in 15 of 19 cases (79%). Thirty-one of the 46 cases receiving treatment (67%) improved, 13 cases (28%) stabilized, and 2 cases (4%) deteriorated. First-line treatment with corticosteroids resulted in satisfactory reduction of symptoms in 21 of 43 patients (49%). Seventeen patients (33%) needed second-line cytostatic treatment, and 10 patients (19%) were treated with tumor necrosis factor-α inhibitors. The majority of patients with neurosarcoidosis present with chronic meningitis without a history of systemic sarcoidosis. The diagnosis can be difficult to make because of the poor sensitivity of most diagnostic tests. Half of patients had a satisfactory reduction of symptoms on first-line therapy.

Published
2016

15. Small fiber neuropathy

Author

Voortman, Mareye, primary, Fritz, Daan, additional, Vogels, Oscar J.M., additional, Eftimov, Filip, additional, van de Beek, Diederik, additional, Brouwer, Matthijs C., additional, and Drent, Marjolein, additional

Published
2017
Full Text
View/download PDF

18. Infliximab treatment in pathology-confirmed neurosarcoidosis.

Author

Fritz D, Timmermans WMC, van Laar JAM, van Hagen PM, Siepman TAM, van de Beek D, and Brouwer MC

Subjects
Adult, Biopsy, Central Nervous System Diseases diagnosis, Central Nervous System Diseases pathology, Central Nervous System Diseases physiopathology, Female, Follow-Up Studies, Humans, Male, Middle Aged, Outcome Assessment, Health Care, Retrospective Studies, Sarcoidosis diagnosis, Sarcoidosis pathology, Sarcoidosis physiopathology, Central Nervous System Diseases drug therapy, Immunologic Factors pharmacology, Infliximab pharmacology, Sarcoidosis drug therapy
Abstract

Objective: To assess the efficacy and risks of treatment with infliximab (anti-tumor necrosis factor alpha) in pathology-confirmed neurosarcoidosis., Methods: In a retrospective study in 2 tertiary referral centers in the Netherlands, we analyzed clinical characteristics, complications, and outcome of patients with neurosarcoidosis treated with infliximab., Results: Twenty-eight patients were identified with a mean age of 42 years. Neurosarcoidosis presented with a cerebral parenchymal localization in 16 (59%), pituitary gland/hypothalamic sarcoidosis in 15 (54%), peripheral nerve involvement in 12 (43%), and chronic meningitis in 11 patients (41%). Initial treatment response after the start of infliximab was complete remission in 6 (21%) and improvement in 14 (50%), whereas 7 patients had stable disease (25%), and 1 (4%) deteriorated and died. At the end of follow-up, with a median of 32 months, 5 patients (18%) had died, and 2 (40%) were using infliximab at the time of death. Tapering or discontinuation of corticosteroids without a relapse was achieved in 19 of 28 patients (68%). In patients with decreasing dosing or discontinuation of infliximab, a relapse occurred in 5 of 19 patients (26%). Complications of infliximab were reported in 10 of 28 patients (36%) and mainly consisted of infections in 8 (29%)., Conclusion: Infliximab is an effective treatment in neurosarcoidosis leading to remission or improvement in 70%. The mortality rate in infliximab-treated patients was substantial, indicating the severity of disease and treatment-associated complications., Classification of Evidence: This study provides Class IV evidence that in people with pathology-confirmed neurosarcoidosis, infliximab is beneficial., (Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results